Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
PRISM BioLab Co. LTD ( (JP:206A) ) just unveiled an announcement.
PRISM BioLab Co., Ltd. has achieved an initial milestone in its drug discovery collaboration with Ono Pharmaceutical Co., Ltd., receiving a milestone payment that will be recorded as business revenue. This achievement marks a significant step in their joint research project aimed at discovering clinical candidate compounds in oncology, leveraging PRISM’s proprietary PepMetics technology. The collaboration is expected to enhance PRISM’s long-term growth and corporate value, with potential royalties from future drug commercialization.
More about PRISM BioLab Co. LTD
PRISM BioLab Co., Ltd. operates in the biotechnology industry, focusing on drug discovery and development. The company specializes in peptide-mimetic technology, particularly targeting protein-protein interactions, with a significant emphasis on the oncology field.
Average Trading Volume: 211,865
Technical Sentiment Signal: Sell
Current Market Cap: Yen5.41B
For detailed information about 206A stock, go to TipRanks’ Stock Analysis page.